International Stem Cell Corporation and Rohto Pharmaceutical Enter Second Stage of Research Agreement

Biotech

International Stem Cell Corporation (OTCQB:ISCO), a California biotech company focused on therapeutic applications of human parthenogenetic stem cells (hpSCs) to develop novel stem cell-based therapies, has announced a continuation of its partnership with Rohto Pharmaceutical Co. (TYO:4527), a Japan-based pharmaceutical company.

According to the press release:

After successfully completing preliminary studies of ISCO’s human parthenogenetic neural stem cells (hpNSCs) Rohto acknowledged that ISCO’s proprietary cells demonstrate consistent high quality and are suitable for further use in Rohto’s research. If Rohto successfully demonstrates hpNSCs’ efficacy in rodent models, which could lead to a possible treatment of a variety of degenerative eye disorders, Rohto will enter into negotiations of a definitive license agreement with ISCO in order to license ISCO’s proprietary technology for therapeutic and commercial use.

Click here to read the full press release from International Stem Cell Corporation.